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Cognitive decline in Alzheimer's disease (AD) is highly related to synaptic 
dysfunction and neuronal loss. In AD and other tauopathies, the 
hyperphosphorylation of tau compromises axonal transport and leads to the 
accumulation of autophagic/vesicular material and the generation of 
dystrophic neurites, contributing to synaptic impairment. In addition to 
phospho-tau, AD brains accumulate amyloid-beta (Aβ). The effect of 
microtubule stabilization has been successfully assessed on tau, but not on 
Aβ pathology. This study evaluated the effect of the brain-penetrant 
microtubule-stabilizing agent, Epothilone D (EpoD) in the progression of 
the disease in a double transgenic mouse model of amyloidosis. 
Young APP751SL/PS1M146L mice (3-month-old) were weekly treated 
with intraperitoneal injections of EpoD (2 mg/kg) or vehicle solution for 3 
months. Memory performance was tested using object-recognition tasks, Y-
maze and Morris water maze. Levels of Aβ, APP-fragments, AT8 
(phospho-tau), ubiquitin, and synaptic markers were analysed by 
Western/dot-blot, immunostaining and image analysis. Somatostin (SOM)-
cell density was calculated by stereology. β- and γ-secretase activities were 
measured. APPswe-N2a cells were treated with EpoD 100 nM for 12/24 
hours. 
EpoD-treated mice improved their performance of cognitive tests, while 
hippocampal phospho-tau and Aβ levels, especially soluble oligomers, 
decreased significantly. β/γ-secretase activities were not affected by EpoD 
in vitro. A significant amelioration of synaptic/neuritic pathology was 
found. Remarkably, EpoD exerted a neuroprotective effect on SOM-
interneurons, a highly AD-vulnerable GABAergic subpopulation. 
In conclusion, EpoD improved microtubule dynamics and axonal transport 
in an AD-like context, reducing tau and Aβ accumulation, and promoting 
neuronal and cognitive protection. These results underline the crosstalk 
between cytoskeleton pathology and proteinopathy. Therefore, microtubule-
stabilizing drugs could be candidates for slowing AD progression at both 
tau and Aβ pathologies. 
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